Endologix, Inc. today announced that a live-case demonstration of its new IntuiTrak™ Delivery System was featured at the International Congress XXII Endovascular Interventions conference in Scottsdale, Ariz. The procedure was performed by Zvonimir Krajcer, MD, Co-director of the Peripheral Vascular Disease Service at the Texas Heart Institute; Edward Diethrich, M.D., Medical Director and Founder of the Arizona Heart Institute; and Venkatesh G. Ramaiah, M.D., Vascular Surgeon at the Arizona Heart Hospital. The endovascular AAA procedure was successfully performed with a percutaneous approach and local anesthesia.
IntuiTrak is an innovative system developed for the minimally invasive delivery and deployment of the Powerlink® stent graft. The device is currently in limited market release following U.S. Food and Drug Administration approval in October 2008. IntuiTrak’s novel design and deployment mechanism simplifies standard vascular delivery of the Powerlink device and provides exceptional accuracy and control. The low-profile delivery system features enhanced flexibility, advanced hemostasis control and a hydrophilic coating to facilitate smooth delivery, particularly in patients with limited or difficult vascular access. Additionally, the delivery catheter has an integrated sheath that minimizes the need to exchange introducers, thereby having the potential to minimize vessel trauma and reduce overall procedure time.
“Due to its low-profile and integrated sheath, IntuiTrak is ideal for the percutaneous treatment of patients with AAA,” said Dr. Krajcer. “I have used the new device in eight cases so far, and have experienced 100% technical success and exceptional patient outcomes.”
“The International Congress provides an excellent opportunity to showcase IntuiTrak before a prestigious audience of physician thought-leaders in the treatment of AAA,” said John McDermott, Endologix President and CEO. “With the procedural advantages of IntuiTrak, combined with the exceptional long-term clinical results of the Powerlink device, we believe we are providing physicians with a compelling technology to treat their AAA patients. We are very encouraged by the physician feedback received to-date and are on schedule for a full-market launch in the U.S. in the second quarter of 2009.”
About International Congress
In its 22nd year, International Congress on Endovascular Interventions is a global educational forum where cardiovascular specialists gather to discuss the newest developments in endovascular interventions through peer-reviewed abstract presentations and live-case demonstrations from Arizona Heart Hospital, Arizona Heart Translational Research Center, and locations around the globe.
Contact:
COMPANY CONTACT:
Endologix, Inc.
John McDermott
President and CEO
(949) 595-7200
www.endologix.com
or
INVESTOR CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss or Jody Cain
bvoss@lhai.com
jcain@lhai.com
(310) 691-7100
www.lhai.com
Source: Endologix, Inc.
IntuiTrak is an innovative system developed for the minimally invasive delivery and deployment of the Powerlink® stent graft. The device is currently in limited market release following U.S. Food and Drug Administration approval in October 2008. IntuiTrak’s novel design and deployment mechanism simplifies standard vascular delivery of the Powerlink device and provides exceptional accuracy and control. The low-profile delivery system features enhanced flexibility, advanced hemostasis control and a hydrophilic coating to facilitate smooth delivery, particularly in patients with limited or difficult vascular access. Additionally, the delivery catheter has an integrated sheath that minimizes the need to exchange introducers, thereby having the potential to minimize vessel trauma and reduce overall procedure time.
“Due to its low-profile and integrated sheath, IntuiTrak is ideal for the percutaneous treatment of patients with AAA,” said Dr. Krajcer. “I have used the new device in eight cases so far, and have experienced 100% technical success and exceptional patient outcomes.”
“The International Congress provides an excellent opportunity to showcase IntuiTrak before a prestigious audience of physician thought-leaders in the treatment of AAA,” said John McDermott, Endologix President and CEO. “With the procedural advantages of IntuiTrak, combined with the exceptional long-term clinical results of the Powerlink device, we believe we are providing physicians with a compelling technology to treat their AAA patients. We are very encouraged by the physician feedback received to-date and are on schedule for a full-market launch in the U.S. in the second quarter of 2009.”
About International Congress
In its 22nd year, International Congress on Endovascular Interventions is a global educational forum where cardiovascular specialists gather to discuss the newest developments in endovascular interventions through peer-reviewed abstract presentations and live-case demonstrations from Arizona Heart Hospital, Arizona Heart Translational Research Center, and locations around the globe.
Contact:
COMPANY CONTACT:
Endologix, Inc.
John McDermott
President and CEO
(949) 595-7200
www.endologix.com
or
INVESTOR CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss or Jody Cain
bvoss@lhai.com
jcain@lhai.com
(310) 691-7100
www.lhai.com
Source: Endologix, Inc.
0 comments:
Post a Comment